Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation
G El Helou, RR Razonable - Expert opinion on drug safety, 2019 - Taylor & Francis
Introduction: Human cytomegalovirus (HCMV) is a major contributor of morbidity and
mortality, and its management is essential for the successful outcome of solid organ and …
mortality, and its management is essential for the successful outcome of solid organ and …
Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation.
G El Helou, RR Razonable - Expert Opinion on Drug Safety, 2019 - europepmc.org
Introduction: Human cytomegalovirus (HCMV) is a major contributor of morbidity and
mortality, and its management is essential for the successful outcome of solid organ and …
mortality, and its management is essential for the successful outcome of solid organ and …
Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation
G El Helou, RR Razonable - Expert Opinion on …, 2019 - mayoclinic.elsevierpure.com
Introduction: Human cytomegalovirus (HCMV) is a major contributor of morbidity and
mortality, and its management is essential for the successful outcome of solid organ and …
mortality, and its management is essential for the successful outcome of solid organ and …
Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation
G El Helou, RR Razonable - Expert opinion on drug safety, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction: Human cytomegalovirus (HCMV) is a major contributor of morbidity and
mortality, and its management is essential for the successful outcome of solid organ and …
mortality, and its management is essential for the successful outcome of solid organ and …